Ron Herings, PharmD, PhD, FISPE

Director
PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands, Netherlands

Poster(s):

• (8) Brodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) Study of a Biological Anti-Psoriatic Drug Across Six European Countries
  Sunday, August 28, 2022

  8:00 AM – 1:45 PM CEST

• (84) Comparing Diabetes Care Outcomes of The Centrally Organized Hoorn Diabetes Care System with Regular Care by General Practitioners in the Netherlands
  Sunday, August 28, 2022

  8:00 AM – 1:45 PM CEST

• (51) Incidence of Lyme Borreliosis in The Dutch General Practice Population: A Large-Scale Population-Based Cohort Study Across the Netherlands Between 2015 and 2019
  Sunday, August 28, 2022

  8:00 AM – 1:45 PM CEST

• (150) Identification of Frail Older Adults Using Routine Primary Care Data: Accuracy of Four Electronically Derived Algorithms
  Saturday, August 27, 2022

  8:00 AM – 6:00 PM CEST

• (166) MINERVA: Metadata for Data Discoverability and Study Replicability in Observational Studies
  Sunday, August 28, 2022

  8:00 AM – 1:45 PM CEST

• (152) Representativeness of the PHARMO Electronic Health Records (EHRs) from Primary Care
  Friday, August 26, 2022

  8:00 AM – 6:00 PM CEST

• (26) Type 2 Diabetes, The Epidemic: Trends in Prevalence, Treatment and Risk-Factor Control, 2004-2020
  Friday, August 26, 2022

  8:00 AM – 6:00 PM CEST